By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Acura Pharmaceuticals Inc. v.
Impax Laboratories Inc.
1:12-cv-01371; filed October
31, 2012 in the District Court of Delaware

Acura Pharmaceuticals Inc. v.
Par Pharmaceutical Inc.
1:12-cv-01372; filed October
31, 2012 in the District Court of Delaware

Acura Pharmaceuticals Inc. v.
Sandoz Inc.
1:12-cv-01373; filed October
31, 2012 in the District Court of Delaware

Acura Pharmaceuticals Inc. v.
Watson Laboratories Inc.-Florida et al.
1:12-cv-01374; filed October
31, 2012 in the District Court of Delaware

• Plaintiff:  Acura
Pharmaceuticals Inc.
• Defendants:  Watson
Laboratories Inc. – Florida; Watson Pharmaceuticals Inc.; Watson Pharma
Inc.

The complaints in these cases
are substantially identical.  Infringement of U.S. Patent No. 7,510,726 ("Methods and
Compositions for Deterring Abuse of Opioid Containing Dosage Forms,"  issued March 31, 2009) following a Paragraph
IV certification as part of defendants' filing of an ANDA to manufacture a
generic version of Oxecta® (oxycodone hydrochloride, used for the management of
acute and chronic moderate to severe pain where the use of an opioid analgesic
is appropriate, marketed by Pfizer). 
View the Impax complaint here.

Esoterix Genetic Laboratories,
LLC et al. v. Life Technologies Corp., et al.
1:12-cv-01173; filed October
31, 2012 in the Middle District of North Carolina

• Plaintiffs:  Esoterix Genetic
Laboratories, LLC; The Johns Hopkins University
• Defendants:   Life Technologies Corp.; Applied
Biosystems, LLC; Ion Torrent Systems, Inc.

Infringement of U.S. Patent
Nos. 6,440,706 (" Digital Amplification,"  issued August 27, 2002), 7,824,889 (same
title, issued November 2, 2010), and 7,915,015 (same title, issued March 29,
2011) based on defendants' manufacture and sale of products, kits, and devices
used in methods for the detection of ratios of genetic sequences in a
biological sample and/or for the detection of allelic imbalances in a biological
sample.  View the complaint here.

Jazz Pharmaceuticals, Inc. v. Roxane
Laboratories, Inc.
2:12-cv-06761; filed October
26, 2012 in the District Court of New Jersey

Infringement of U.S. Patent
No. 8,263,650 (" Microbiologically
Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of
Narcolepsy,"  issued September 11, 2012) following a
Paragraph IV certification as part of Roxane's filing of an ANDA to manufacture
a generic version of Jazz's Xyrem® (sodium oxybate, used to treat
narcolepsy).  View the complaint here.